Connect with us

Published

on

Elon Musk’s Neuralink, a medical device company, is under federal investigation for potential animal-welfare violations amid internal staff complaints that its animal testing is being rushed, causing needless suffering and deaths, according to documents reviewed by Reuters and sources familiar with the investigation and company operations.

Neuralink is developing a brain implant it hopes will help paralysed people walk again and cure other neurological ailments. The federal probe, which has not been previously reported, was opened in recent months by the US Department of Agriculture’s Inspector General at the request of a federal prosecutor, according to two sources with knowledge of the investigation. The probe, one of the sources said, focuses on violations of the Animal Welfare Act, which governs how researchers treat and test some animals.

The investigation has come at a time of growing employee dissent about Neuralink’s animal testing, including complaints that pressure from CEO Musk to accelerate development has resulted in botched experiments, according to a Reuters review of dozens of Neuralink documents and interviews with more than 20 current and former employees. Such failed tests have had to be repeated, increasing the number of animals being tested and killed, the employees say. The company documents include previously unreported messages, audio recordings, emails, presentations and reports.

Musk and other Neuralink executives did not respond to requests for comment.

Reuters could not determine the full scope of the federal investigation or whether it involved the same alleged problems with animal testing identified by employees in Reuters interviews. A spokesperson for the USDA inspector general declined to comment. US regulations don’t specify how many animals companies can use for research, and they give significant leeway to scientists to determine when and how to use animals in experiments. Neuralink has passed all USDA inspections of its facilities, regulatory filings show.

In all, the company has killed about 1,500 animals, including more than 280 sheep, pigs and monkeys, following experiments since 2018, according to records reviewed by Reuters and sources with direct knowledge of the company’s animal-testing operations. The sources characterised that figure as a rough estimate because the company does not keep precise records on the number of animals tested and killed. Neuralink has also conducted research using rats and mice.

The total number of animal deaths does not necessarily indicate that Neuralink is violating regulations or standard research practices. Many companies routinely use animals in experiments to advance human health care, and they face financial pressure to quickly bring products to market. The animals are typically killed when experiments are completed, often so they can be examined post-mortem for research purposes.

But current and former Neuralink employees say the number of animal deaths is higher than it needs to be for reasons related to Musk’s demands to speed research. Through company discussions and documents spanning several years, along with employee interviews, Reuters identified four experiments involving 86 pigs and two monkeys that were marred in recent years by human errors. The mistakes weakened the experiments’ research value and required the tests to be repeated, leading to more animals being killed, three of the current and former staffers said. The three people attributed the mistakes to a lack of preparation by a testing staff working in a pressure-cooker environment.

One employee, in a message seen by Reuters, wrote an angry missive earlier this year to colleagues about the need to overhaul how the company organises animal surgeries to prevent “hack jobs.” The rushed schedule, the employee wrote, resulted in under-prepared and over-stressed staffers scrambling to meet deadlines and making last-minute changes before surgeries, raising risks to the animals.

Musk has pushed hard to accelerate Neuralink’s progress, which depends heavily on animal testing, current and former employees said. Earlier this year, the chief executive sent staffers a news article about Swiss researchers who developed an electrical implant that helped a paralyzed man to walk again. “We could enable people to use their hands and walk again in daily life!” he wrote to staff at 6:37 a.m. Pacific Time on Feb. 8. Ten minutes later, he followed up: “In general, we are simply not moving fast enough. It is driving me nuts!”

On several occasions over the years, Musk has told employees to imagine they had a bomb strapped to their heads in an effort to get them to move faster, according to three sources who repeatedly heard the comment. On one occasion a few years ago, Musk told employees he would trigger a “market failure” at Neuralink unless they made more progress, a comment perceived by some employees as a threat to shut down operations, according to a former staffer who heard his comment.

Five people who’ve worked on Neuralink’s animal experiments told Reuters they had raised concerns internally. They said they had advocated for a more traditional testing approach, in which researchers would test one element at a time in an animal study and draw relevant conclusions before moving on to more animal tests. Instead, these people said, Neuralink launches tests in quick succession before fixing issues in earlier tests or drawing complete conclusions. The result: More animals overall are tested and killed, in part because the approach leads to repeated tests.

One former employee who asked management several years ago for more deliberate testing was told by a senior executive it wasn’t possible given Musk’s demands for speed, the employee said. Two people told Reuters they left the company over concerns about animal research.

The problems with Neuralink’s testing have raised questions internally about the quality of the resulting data, three current or former employees said. Such problems could potentially delay the company’s bid to start human trials, which Musk has said the company wants to do within the next six months. They also add to a growing list of headaches for Musk, who is facing criticism of his management of Twitter, which he recently acquired for $44 billion. Musk also continues to run electric carmaker Tesla Inc and rocket company SpaceX.

The US Food and Drug Administration is in charge of reviewing the company’s applications for approval of its medical device and associated trials. The company’s treatment of animals during research, however, is regulated by the USDA under the Animal Welfare Act. The FDA didn’t immediately comment.

Missed deadlines, botched experiments

Musk’s impatience with Neuralink has grown as the company, which launched in 2016, has missed his deadlines on several occasions to win regulatory approval to start clinical trials in humans, according to company documents and interviews with eight current and former employees.

Some Neuralink rivals are having more success. Synchron, which was launched in 2016 and is developing a different implant with less ambitious goals for medical advances, received FDA approval to start human trials in 2021. The company’s device has allowed paralyzed people to text and type by thinking alone. Synchron has also conducted tests on animals, but it has killed only about 80 sheep as part of its research, according to studies of the Synchron implant reviewed by Reuters. Musk approached Synchron about a potential investment, Reuters reported in August.

Synchron declined to comment.

In some ways, Neuralink treats animals quite well compared to other research facilities, employees said in interviews, echoing public statements by Musk and other executives. Company leaders have boasted internally of building a “Monkey Disneyland” in the company’s Austin, Texas facility where lab animals can roam, a former employee said. In the company’s early years, Musk told employees he wanted the monkeys at his San Francisco Bay Area operation to live in a “monkey Taj Mahal,” said a former employee who heard the comment. Another former employee recalled Musk saying he disliked using animals for research but wanted to make sure they were “the happiest animals” while alive.

The animals have fared less well, however, when used in the company’s research, current and former employees say.

The first complaints about the company’s testing involved its initial partnership with University of California, Davis, to conduct the experiments. In February, an animal rights group, the Physicians Committee for Responsible Medicine, filed a complaint with the USDA accusing the Neuralink-UC Davis project of botching surgeries that killed monkeys and publicly released its findings. The group alleged that surgeons used the wrong surgical glue twice, which led to two monkeys suffering and ultimately dying, while other monkeys had different complications from the implants.

The company has acknowledged it killed six monkeys, on the advice of USC Davis veterinary staff, because of health problems caused by experiments. It called the issue with the glue a “complication” from the use of an “FDA-approved product.” In response to a Reuters inquiry, a USC Davis spokesperson shared a previous public statement defending its research with Neuralink and saying it followed all laws and regulations.

A federal prosecutor in the Northern District of California referred the animal rights group’s complaint to the USDA Inspector General, which has since launched a formal probe, according to a source with direct knowledge of the investigation. USDA investigators then inquired about the allegations involving the UC Davis monkey research, according to two sources familiar with the matter and emails and messages reviewed by Reuters.

The probe is concerned with the testing and treatment of animals in Neuralink’s own facilities, one of the sources said, without elaborating. In 2020, Neuralink brought the program in-house, and has since built its extensive facilities in California and Texas.

A spokesperson for the US attorney’s office for the Northern District of California declined to comment.

Delcianna Winders, director of the Animal Law and Policy Institute at the Vermont Law and Graduate School, said it is “very unusual” for the USDA inspector general to investigate animal research facilities. Winders, an animal-testing opponent who has criticised Neuralink, said the inspector general has primarily focused in recent years on dog fighting and cockfighting actions when applying the Animal Welfare Act.

It’s hard on the little piggies

The mistakes leading to unnecessary animal deaths included one instance in 2021, when 25 out of 60 pigs in a study had devices that were the wrong size implanted in their heads, an error that could have been avoided with more preparation, according to a person with knowledge of the situation and company documents and communications reviewed by Reuters.

The mistake raised alarms among Neuralink’s researchers. In May 2021, Viktor Kharazia, a scientist, wrote to colleagues that the mistake could be a “red flag” to FDA reviewers of the study, which the company planned to submit as part of its application to begin human trials. His colleagues agreed, and the experiment was repeated with 36 sheep, according to the person with knowledge of the situation. All the animals, both the pigs and the sheep, were killed after the procedures, the person said.

Kharazia did not comment in response to requests.

On another occasion, staff accidentally implanted Neuralink’s device on the wrong vertebra of two different pigs during two separate surgeries, according to two sources with knowledge of the matter and documents reviewed by Reuters. The incident frustrated several employees who said the mistakes – on two separate occasions – could have easily been avoided by carefully counting the vertebrae before inserting the device.

Company veterinarian Sam Baker advised his colleagues to immediately kill one of the pigs to end her suffering.

“Based on low chance of full recovery … and her current poor psychological well-being, it was decided that euthanasia was the only appropriate course of action,” Baker wrote colleagues about one of the pigs a day after the surgery, adding a broken heart emoji.

Baker did not comment on the incident.

Employees have sometimes pushed back on Musk’s demands to move fast. In a company discussion several months ago, some Neuralink employees protested after a manager said that Musk had encouraged them to do a complex surgery on pigs soon. The employees resisted on the grounds that the surgery’s complexity would lengthen the amount of time the pigs would be under anesthesia, risking their health and recovery. They argued they should first figure out how to cut down the time it would take to do the surgery.

“It’s hard on the little piggies,” one of the employees said, referring to the lengthy period under anesthesia.

In September, the company responded to employee concerns about its animal testing by holding a town hall to explain its processes. It soon after opened up the meetings to staff of its federally-mandated board that reviews the animal experiments.

Neuralink executives have said publicly that the company tests animals only when it has exhausted other research options, but documents and company messages suggest otherwise. During a November 30 presentation the company broadcast on YouTube, for example, Musk said surgeries were used at a later stage of the process to confirm that the device works rather than to test early hypotheses. “We’re extremely careful,” he said, to make sure that testing is “confirmatory, not exploratory,” using animal testing as a last resort after trying other methods.

In October, a month before Musk’s comments, Autumn Sorrells, the head of animal care, ordered employees to scrub “exploration” from study titles retroactively and stop using it in the future.

Sorrells did not comment in response to requests.

Neuralink records reviewed by Reuters contained numerous references over several years to exploratory surgeries, and three people with knowledge of the company’s research strongly rejected the assertion that Neuralink avoids exploratory tests on animals. Company discussions reviewed by Reuters showed several employees expressing concerns about Sorrells’ request to change exploratory study descriptions, saying it would be inaccurate and misleading.

One noted that the request seemed designed to provide “better optics” for Neuralink.

© Thomson Reuters 2022


Affiliate links may be automatically generated – see our ethics statement for details.

Continue Reading

Science

ISRO Postpones Docking of SpaDeX Satellites Again

Published

on

By

ISRO Postpones Docking of SpaDeX Satellites Again

The Indian Space Research Organisation (ISRO) has postponed its Space Docking Experiment (SpaDex) mission which was scheduled for Thursday, after the satellites drifted more than expected during a manoeuvre, ISRO said in a statement on Wednesday.

This is the second time that the docking experiment has been postponed.
It was originally scheduled for January 7.

In a post on X, ISRO said, “While making a maneuver to reach 225 m between satellites, the drift was found to be more than expected post non-visibility period.”

“The planned docking for tomorrow is postponed. Satellites are safe,” it added.

Earlier, on Monday, the ISRO had postponed the docking of its SpaDex mission program, initially scheduled for January 7, 2025. The new date for the docking has been set for January 9, 2025. ISRO has not provided any specific reason for the schedule change.

On December 30, ISRO achieved a historic feat by launching PSLV-C60 with SpaDeX and innovative payloads.

The SpaDeX mission is a cost-effective technology demonstrator mission for the demonstration of in-space docking using two small spacecraft launched by PSLV. The primary objective of the SpaDeX mission is to develop and demonstrate the technology needed for the rendezvous, docking, and undocking of two small spacecraft (SDX01, which is the Chaser, and SDX02, the Target, nominally) in a low-Earth circular orbit.

Union Minister of State (Independent Charge) of the Ministry of Earth Sciences, Jitendra Singh, last week said that the SpaDeX mission was named “Bharatiya Docking Technology” because it is purely an indigenous mission, and India is carrying out the first such experiment related to docking technology.

The Union MoS further stated that SpaDeX’s mission very much aligns with Prime Minister Narendra Modi’s vision of “Aatmanirbhar Bharat.”

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)

Catch the latest from the Consumer Electronics Show on Gadgets 360, at our CES 2025 hub.

Continue Reading

Science

Blue Origin New Glenn Set for Launch on January 10 from Cape Canaveral

Published

on

By

Blue Origin New Glenn Set for Launch on January 10 from Cape Canaveral

The highly anticipated debut launch of Blue Origin’s New Glenn rocket has been scheduled for January 10, 2025. The heavy-lift rocket, designed for both commercial and government missions, will take off from Florida’s Cape Canaveral Space Force Station. A launch window of three hours, beginning at 1 a.m. EST, has been announced. The rocket’s inaugural flight marks a significant milestone for Blue Origin as the company aims to validate its capabilities and establish itself as a major player in the space industry.

New Glenn’s Mission and Capabilities

According to Blue Origin, as reported by space.com, the New Glenn rocket is a reusable, 320-foot-tall launch vehicle capable of carrying 50 tons (45 metric tons) to low Earth orbit (LEO). The NG-1 mission will test the company’s Blue Ring spacecraft platform, which is designed to support a variety of orbital payloads. This demonstration will include assessments of communication systems, in-space telemetry, and ground-based tracking capabilities. The payload will remain aboard the rocket’s second stage for a six-hour mission, as stated by Blue Origin.

Booster Recovery and Future Goals

The mission will also attempt a recovery of the rocket’s first stage booster, which will land on a ship stationed in the Atlantic Ocean, as per reports from space.com. The company’s senior vice president, Jarrett Jones, emphasised the importance of the flight, stating that rigorous preparations had been undertaken but that true insights could only be gained through actual launch experiences.

NG-1 is a critical step toward securing certification for U.S. national security missions. A successful outcome would bring Blue Origin closer to fulfilling these high-stakes contracts, further solidifying its position in the competitive aerospace sector.

This launch will serve as a proving ground for the New Glenn system, with valuable data expected to inform future missions and technology advancements.

Catch the latest from the Consumer Electronics Show on Gadgets 360, at our CES 2025 hub.

Continue Reading

Science

Spiders Detect Smells Through Leg Hairs, Claims New Study

Published

on

By

Spiders Detect Smells Through Leg Hairs, Claims New Study

New research has revealed that spiders use specialised hairs on their legs to detect airborne scents, offering fresh insights into the sensory abilities of these arachnids. This discovery has resolved a long-standing question about how spiders, which lack antennae like insects, can identify odours such as pheromones. Male spiders were observed using olfactory hairs, known as wall-pore sensilla, to sense sex pheromones emitted by females. This mechanism underscores their ability to locate potential mates through chemical signals.

Olfactory Sensilla Identified

According to a study, published in the Proceedings of the National Academy of Sciences, the wall-pore sensilla were found on the upper legs of adult male wasp spiders (Argiope bruennichi). These microscopic structures are believed to be critical for detecting pheromones. High-resolution scanning electron microscopy revealed thousands of these sensilla, which were absent in females and juvenile males. This specific distribution supports their role in mate detection. Researchers emphasised to phys.org that these findings have mapped and identified the elusive sensilla, previously thought to be absent in spiders.

Response to Pheromones

Experiments demonstrated the sensitivity of these sensilla to pheromone compounds. Tiny amounts of the substance, such as 20 nanograms, elicited significant neuronal responses. The experiments involved exposing the sensilla to pheromone puffs, and responses were observed consistently across various leg pairs. The researchers concluded that spiders’ olfactory systems rival the sensitivity seen in insects, highlighting their advanced chemical detection capabilities.

Broader Implications

The study explored 19 other spider species and confirmed the presence of wall-pore sensilla in most male spiders, suggesting that this trait evolved multiple times. However, it was noted that some primitive species lack these structures. Future research is expected to investigate how female spiders detect smells, the types of chemicals relevant to their behaviours, and the evolutionary aspects of olfaction in spiders.

This breakthrough provides a foundation for understanding the sophisticated sensory mechanisms that govern spider behaviour.

Catch the latest from the Consumer Electronics Show on Gadgets 360, at our CES 2025 hub.

Continue Reading

Trending